| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G/A | 2024-02-14 | TANG CAPITAL PARTNERS LP | TCR2 THERAPEUTICS INC. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2023-05-05 | TANG CAPITAL PARTNERS LP | TCR2 THERAPEUTICS INC. | 4,215,864 | 10.7% | EDGAR |
| SC 13G/A | 2023-02-14 | TANG CAPITAL PARTNERS LP | TCR2 THERAPEUTICS INC. | 2,738,947 | 7.1% | EDGAR |
| SC 13G/A | 2023-02-09 | K2 PRINCIPAL FUND, L.P. | TCR2 THERAPEUTICS INC. | 10 | 0.0% | EDGAR |
| SC 13G | 2022-09-01 | K2 PRINCIPAL FUND, L.P. | TCR2 THERAPEUTICS INC. | 1,950,628 | 5.0% | EDGAR |
| SC 13G | 2022-07-08 | BlackRock Inc. | TCR2 THERAPEUTICS INC. | 1,037,694 | 2.7% | EDGAR |
| SC 13G | 2022-03-04 | TANG CAPITAL PARTNERS LP | TCR2 THERAPEUTICS INC. | 2,800,000 | 7.3% | EDGAR |
| SC 13G/A | 2022-02-14 | Redmile Group, LLC | TCR2 THERAPEUTICS INC. | 1,346,058 | 3.5% | EDGAR |
| SC 13G/A | 2022-02-03 | BlackRock Inc. | TCR2 THERAPEUTICS INC. | 2,401,745 | 6.3% | EDGAR |
| SC 13G/A | 2021-11-10 | WELLINGTON MANAGEMENT GROUP LLP | TCR2 THERAPEUTICS INC. | 1,131,347 | 3.0% | EDGAR |
| SC 13G/A | 2021-02-16 | Redmile Group, LLC | TCR2 THERAPEUTICS INC. | 2,832,888 | 8.5% | EDGAR |
| SC 13G/A | 2021-02-16 | ArrowMark Colorado Holdings LLC | TCR2 THERAPEUTICS INC. | 1,167,220 | 3.5% | EDGAR |
| SC 13G/A | 2021-02-09 | Upnorth Investment Ltd | TCR2 THERAPEUTICS INC. | 1,281,392 | 3.8% | EDGAR |
| SC 13G | 2021-02-02 | BlackRock Inc. | TCR2 THERAPEUTICS INC. | 2,603,539 | 7.8% | EDGAR |
| SC 13G | 2021-01-11 | WELLINGTON MANAGEMENT GROUP LLP | TCR2 THERAPEUTICS INC. | 3,753,364 | 11.2% | EDGAR |
| SC 13G/A | 2020-02-14 | Redmile Group, LLC | TCR2 THERAPEUTICS INC. | 1,799,188 | 7.5% | EDGAR |
| SC 13G | 2020-02-14 | ArrowMark Colorado Holdings LLC | TCR2 THERAPEUTICS INC. | 1,269,766 | 5.3% | EDGAR |
| SC 13G/A | 2020-02-10 | Upnorth Investment Ltd | TCR2 THERAPEUTICS INC. | 2,137,419 | 8.9% | EDGAR |
| SC 13G | 2020-01-29 | F2 Capital I 2015 Ltd | TCR2 THERAPEUTICS INC. | 1,561,612 | 6.5% | EDGAR |
| SC 13D | 2019-03-04 | MPM BioVentures 2014, L.P. | TCR2 THERAPEUTICS INC. | 3,056,272 | 13.2% | EDGAR |